MedTrace Logo

Apixaban Discontinuation Prior to Major Surgery

NCT02935751 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2018-09-12

No results posted yet for this study

Summary

The ADIOS study is a prospective, observational study will evaluate one hundred and thirty (130) patients with non-valvular atrial fibrillation who are currently receiving treatment with apixaban as indicated to reduce the risk of stroke or systemic embolism, and who require an elective major surgical or invasive procedure will be included in the study. The purpose of the study is to evaluate the efficacy of the recommended pre-procedure washout period of 48 hours.

Conditions

Interventions

OTHER

Lab tests for plasma levels of apixaban and anti-10a factor

All patients will have a blood draw at 48 hours prior to elective surgical procedure and then a second blood draw on the morning of the procedure to test apixaban plasma and anti-Xa levels.

Sponsors & Collaborators

Principal Investigators

  • Geno J. Merli, MD · Thomas Jefferson University

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2018-07-31
Completion
2018-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02935751 on ClinicalTrials.gov